ROIV

Roivant Sciences
D

ROIV

Arincen25/100B
40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Q2 FY2027 results
EPS-0.27+26.4%Revenue35.12M+710.0%
OverviewFinancialsForecastEarningsCompany

Roivant Sciences revenue 2019–2026

Roivant Sciences's revenue in Q2 FY2026, the three months to 30 September 2026, was 35.12M USD, up 2,135.6% on the same quarter a year before. Roivant Sciences's revenue over the last twelve months was 41.08M USD, up 102.1% on the twelve months before. In fiscal year 2025 it was 8.26M USD, down 71.6% on the year before.

Last updated 10 Nov 2026 · Next report 5 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202641.08M+102.09%36.43M-344.35M
FY202531 Mar 20268.26M-71.57%6.98M-299.77M
FY202431 Mar 202529.05M-11.19%28.14M-171.98M
FY202331 Mar 202432.71M+3.75%31.11M4.35B
FY202231 Mar 202331.53M-42.97%28.50M-1.01B
FY202131 Mar 202255.29M+132.34%46.32M-845.26M
FY202031 Mar 202123.80M-64.85%21.74M-809.23M
FY201931 Mar 202067.69M—66.56M1.20B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Roivant Sciences revenue growth by segment

Q2 FY2026 against Q2 FY2025

Product30.97M
—

Roivant Sciences revenue by segment over time

Reportable Product License, Milestone and Other Revenue
Fiscal yearReportableProductLicense, Milestone and Other Revenue
FY20258.26M — —
FY2023— 75.06M +168.0%49.74M +49.5%
FY2022— 28.01M 33.27M

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Roivant Sciences's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.